Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. ADR (NQ: NBTX )

4.400 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2
Open 4.400
Bid (Size) 3.280 (57)
Ask (Size) 5.800 (10)
Prev. Close 4.400
Today's Range 4.400 - 4.400
52wk Range 4.140 - 8.962
Shares Outstanding 34,432,122
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
NANOBIOTIX to Participate in Multiple Investor Conferences in November
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire

Performance

YTD
-40.10%
-40.10%
1 Month
-15.22%
-15.22%
3 Month
-13.56%
-13.56%
6 Month
-30.38%
-30.38%
1 Year
-24.66%
-24.66%

More News

Read More
NANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces New Data Showing Disease Control and Tumor Response in Patients Treated With RT-Activated NBTXR3 Followed By anti-PD-1 For 2l+ R/M HNSCC Naïve or Resistant to Prior anti-PD-1 Therapy
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
Why XP Shares Are Trading Lower By Around 12%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
From Nanobiotix S.A.
Via GlobeNewswire
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
From Nanobiotix S.A.
Via GlobeNewswire
NANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
From Nanobiotix S.A.
Via GlobeNewswire
CarMax Reports Downbeat Earnings, Joins Lovesac And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
Via Benzinga
Topics Stocks
Exposures US Equities
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
Nanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
From Nanobiotix S.A.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
Why Science Applications International Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.